Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$51.76 -1.5%	$46.82	$21.72 ▼ $52.85	$10.05B	1.23	3.00 million shs	3.00 million shs
BHC Bausch Health Cos	$7.41 +3.6%	$6.73	$4.25 ▼ $9.85	$2.65B	0.41	4.52 million shs	2.19 million shs
MRNA Moderna	$24.09 -1.6%	$29.09	$23.15 ▼ $79.96	$9.52B	1.83	9.44 million shs	8.27 million shs
QGEN QIAGEN	$46.53 +0.9%	$48.71	$37.63 ▼ $51.88	$10.26B	0.64	1.49 million shs	1.97 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+6.01%	+4.66%	+13.49%	+52.86%	+111.12%
BHC Bausch Health Cos	-1.51%	-4.40%	+4.90%	+58.17%	+21.54%
MRNA Moderna	-2.51%	-6.67%	-25.08%	-7.87%	-68.77%
QGEN QIAGEN	-4.02%	-6.23%	-9.81%	+2.09%	+3.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.1775 of 5 stars	3.5	2.0	0.0	3.9	2.2	3.3	0.6
BHC Bausch Health Cos	4.3082 of 5 stars	2.0	4.0	0.0	4.0	2.8	3.3	1.9
MRNA Moderna	4.5908 of 5 stars	4.0	2.0	0.0	4.6	2.7	2.5	1.3
QGEN QIAGEN	3.9473 of 5 stars	1.1	2.0	1.7	4.5	3.5	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	3.00	Buy	$62.18	20.12% Upside
BHC Bausch Health Cos	2.00	Hold	$9.00	21.46% Upside
MRNA Moderna	2.04	Hold	$42.88	78.01% Upside
QGEN QIAGEN	2.27	Hold	$49.69	6.77% Upside

Current Analyst Ratings Breakdown

Latest BHC, QGEN, MRNA, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/29/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $70.00
8/22/2025	MRNA Moderna	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $15.00
8/7/2025	QGEN QIAGEN	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/7/2025	QGEN QIAGEN	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$48.00 ➝ $50.00
8/6/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$55.00 ➝ $57.00
8/6/2025	BBIO BridgeBio Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $61.00
8/4/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $31.00
8/1/2025	MRNA Moderna	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$32.00
8/1/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$26.00
8/1/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
8/1/2025	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$32.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	44.59	N/A	N/A	($9.30) per share	-5.57
BHC Bausch Health Cos	$9.63B	0.28	$8.05 per share	0.92	$0.40 per share	18.53
MRNA Moderna	$3.24B	2.90	N/A	N/A	$24.16 per share	1.00
QGEN QIAGEN	$1.98B	5.23	$3.23 per share	14.40	$15.77 per share	2.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$4.09	N/A	N/A	N/A	-329.25%	N/A	-85.69%	11/11/2025 (Estimated)
BHC Bausch Health Cos	-$46M	$0.26	28.50	1.59	N/A	0.99%	-852.36%	5.25%	10/29/2025 (Estimated)
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	11/6/2025 (Estimated)
QGEN QIAGEN	$83.59M	$1.69	27.49	18.92	2.42	18.30%	14.77%	8.87%	11/5/2025 (Estimated)

Latest BHC, QGEN, MRNA, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.83	-$0.95	-$0.12	-$0.95	$98.46 million	$110.57 million
8/5/2025	Q2 2025	QGEN QIAGEN	$0.60	$0.60	N/A	$0.44	$523.97 million	$533.54 million
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.97	$0.90	-$0.07	$0.40	$2.47 billion	$2.57 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
QGEN QIAGEN	$0.25	0.54%	N/A	14.79%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	5.19	5.08
BHC Bausch Health Cos	141.90	1.31	0.98
MRNA Moderna	N/A	3.93	3.77
QGEN QIAGEN	0.25	1.61	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BHC Bausch Health Cos	78.65%
MRNA Moderna	75.33%
QGEN QIAGEN	70.00%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BHC Bausch Health Cos	8.05%
MRNA Moderna	11.00%
QGEN QIAGEN	9.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	191.17 million	156.38 million	Optionable
BHC Bausch Health Cos	20,700	370.13 million	340.33 million	Optionable
MRNA Moderna	5,800	389.08 million	346.28 million	Optionable
QGEN QIAGEN	5,765	222.29 million	202.29 million	Optionable

BHC, QGEN, MRNA, and BBIO Headlines

Recent News About These Companies

Qiagen N.V. $QGEN Shares Sold by Earnest Partners LLC

August 29 at 8:35 AM | marketbeat.com

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

August 28 at 5:08 PM | businesswire.com

QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds

August 28 at 12:11 PM | businesswire.com

QIAGEN N.V. $QGEN Holdings Trimmed by Hsbc Holdings PLC

August 28 at 4:41 AM | marketbeat.com

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds

August 28 at 2:05 AM | businesswire.com

QIAGEN N.V. $QGEN Shares Acquired by Price T Rowe Associates Inc. MD

August 27 at 5:04 AM | marketbeat.com

Qiagen Announces Major BlackRock Shareholding

August 26 at 12:08 AM | msn.com

Qiagen Receives Notification of BlackRock’s Significant Stake

August 26 at 12:08 AM | msn.com

Oak Harvest Investment Services Invests $3.19 Million in Qiagen N.V. $QGEN

August 26 at 7:39 AM | marketbeat.com

144,691 Shares in Qiagen N.V. $QGEN Bought by Groupe la Francaise

August 26 at 5:40 AM | marketbeat.com

Korea Investment CORP Sells 17,567 Shares of QIAGEN N.V. $QGEN

August 26 at 4:15 AM | marketbeat.com

Brokerages Set QIAGEN N.V. (NYSE:QGEN) PT at $49.69

August 25, 2025 | americanbankingnews.com

Martingale Asset Management L P Sells 87,406 Shares of Qiagen N.V. $QGEN

August 24, 2025 | marketbeat.com

Invesco Ltd. Purchases 53,383 Shares of Qiagen N.V. $QGEN

August 24, 2025 | marketbeat.com

Qiagen N.V. (NYSE:QGEN) Given Consensus Recommendation of "Hold" by Brokerages

August 24, 2025 | marketbeat.com

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis

August 21, 2025 | seekingalpha.com

Wellington Management Group LLP Increases Holdings in Qiagen N.V. $QGEN

August 21, 2025 | marketbeat.com

Russell Investments Group Ltd. Reduces Stake in QIAGEN N.V. $QGEN

August 21, 2025 | marketbeat.com

Stocks Showing Rising Market Leadership: Qiagen Earns 81 RS Rating

August 20, 2025 | msn.com

Qiagen Executive Sells Significant Shareholding

August 19, 2025 | msn.com

QIAGEN N.V. $QGEN Holdings Raised by Public Sector Pension Investment Board

August 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC, QGEN, MRNA, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$51.76 -0.81 (-1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$51.50 -0.26 (-0.50%)

As of 07:28 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Bausch Health Cos NYSE:BHC

$7.41 +0.26 (+3.64%)

Closing price 03:59 PM Eastern

Extended Trading

$7.42 +0.01 (+0.13%)

As of 07:17 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Moderna NASDAQ:MRNA

$24.09 -0.38 (-1.55%)

Closing price 04:00 PM Eastern

Extended Trading

$24.16 +0.07 (+0.29%)

As of 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

QIAGEN NYSE:QGEN

$46.53 +0.39 (+0.85%)

Closing price 03:59 PM Eastern

Extended Trading

$46.77 +0.24 (+0.51%)

As of 05:38 PM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time